PGC-1alpha as modifier of onset age in Huntington disease. - Wikidata - wikimedia - TriplyDB

PGC-1alpha as modifier of onset age in Huntington disease.

PGC-1alpha as modifier of onset age in Huntington disease.

http://www.wikidata.org/entity/Q42927080

about

PGC-1α, mitochondrial dysfunction, and Huntington's disease NMDA receptor gene variations as modifiers in Huntington disease: a replication study Shaping the role of mitochondria in the pathogenesis of Huntington's disease Mitochondrial dysfunction in neurodegenerative diseases Integration of β-catenin, sirtuin, and FOXO signaling protects from mutant huntingtin toxicity TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntington's disease.Population stratification may bias analysis of PGC-1α as a modifier of age at Huntington disease motor onset.Genetic background modulates behavioral impairments in R6/2 mice and suggests a role for dominant genetic modifiers in Huntington’s disease pathogenesis.Minireview: the SRC family of coactivators: an entrée to understanding a subset of polygenic diseases?Mice lacking the transcriptional coactivator PGC-1α exhibit alterations in inhibitory synaptic transmission in the motor cortex.Association of PGC-1alpha polymorphisms with age of onset and risk of Parkinson's disease Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation.A greatly extended PPARGC1A genomic locus encodes several new brain-specific isoforms and influences Huntington disease age of onset.Genetic analysis of polymorphisms in the kalirin gene for association with age-at-onset in European Huntington disease patients.PGC-1α provides a transcriptional framework for synchronous neurotransmitter release from parvalbumin-positive interneurons.Developmental alterations in motor coordination and medium spiny neuron markers in mice lacking pgc-1α Meclizine is neuroprotective in models of Huntington's disease.Pgc-1α overexpression downregulates Pitx3 and increases susceptibility to MPTP toxicity associated with decreased Bdnf.Localization of sequence variations in PGC-1α influence their modifying effect in Huntington disease.Increase of angiotensin II type 1 receptor auto-antibodies in Huntington's disease.PGC-1 coactivators in the control of energy metabolism.The V471A polymorphism in autophagy-related gene ATG7 modifies age at onset specifically in Italian Huntington disease patients.Mutual exacerbation of peroxisome proliferator-activated receptor γ coactivator 1α deregulation and α-synuclein oligomerization Mitogen- and stress-activated protein kinase 1-induced neuroprotection in Huntington's disease: role on chromatin remodeling at the PGC-1-alpha promoter.PGC-1alpha downstream transcription factors NRF-1 and TFAM are genetic modifiers of Huntington disease.A single nucleotide polymorphism in the coding region of PGC-1α is a male-specific modifier of Huntington disease age-at-onset in a large European cohort.Exploring Genetic Factors Involved in Huntington Disease Age of Onset: E2F2 as a New Potential Modifier Gene.Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease β-Defensin Genomic Copy Number Does Not Influence the Age of Onset in Huntington's Disease.Insulin and Insulin-Sensitizing Drugs in Neurodegeneration: Mitochondria as Therapeutic Targets.Attenuation of polyglutamine-induced toxicity by enhancement of mitochondrial OXPHOS in yeast and fly models of aging.Molecular mechanisms and potential therapeutical targets in Huntington's disease.Energy deficit in Huntington disease: why it matters.Targeting Huntington's disease through histone deacetylases.Prospects for neuroprotective therapies in prodromal Huntington's disease.Genetic modifiers of Huntington's disease.Huntington's Disease: Relationship Between Phenotype and Genotype.Psychiatric and cognitive symptoms in Huntington's disease are modified by polymorphisms in catecholamine regulating enzyme genes.Interferon-beta affects mitochondrial activity in CD4+ lymphocytes: Implications for mechanism of action in multiple sclerosis.Huntington's disease: the case for genetic modifiers.

P2860

Q27001671-D246A293-245F-4386-A5F9-033CEEEA3346 Q27499977-3ED68C9C-55AF-4EC4-B176-47C93E77B977 Q28384036-8D5B381D-7A58-4DCA-BC14-94BC12C68E3E Q28387647-1292518F-E806-43EE-9EE4-75B3453E16DD Q28507004-083BB456-B4EA-42A7-948A-FCA559C250E4 Q30417570-7D4108D4-D261-4DDB-A25F-C1EC75414921 Q30424048-62CA46F5-C54E-4E98-88C6-7F588D391939 Q30467288-663335D5-68A4-4CAC-8CE7-14080F665742 Q33634287-8D6E7DAB-1459-44CB-8929-47D68381F0AB Q33799027-FDC6ACFA-3028-4200-8FE4-85C7BA598350 Q33906098-982F4043-3D79-4063-8B30-C46C7B5441CA Q34042260-8CACEA16-4413-444F-9067-7429295D1E3D Q34275231-513EEBCA-A59B-4633-B473-39F2732B94BB Q34312581-5D98F2F6-766B-4F2F-99D8-4C1265F8C835 Q34383492-111916AC-5DB7-4D3D-9786-1B497EDEB937 Q34391101-5A1FD971-F5EA-49F6-B04D-23611127F5AB Q34424265-3D4C7012-DEED-4F4D-8E5A-94D94BDB4D8F Q34473733-D0FC33AC-3E91-4D51-A646-AC5084B04800 Q34498391-CA66001D-56D5-4576-9559-98C38ECCB52F Q34581918-F4DA2FC0-322D-433A-B837-062358DEA1BB Q34712077-CE8653C1-655B-4DA6-96FB-BD06709448CB Q34873673-1D1CE8F5-0D9E-4F1E-A4E4-AC701073331B Q34944325-3F43491F-0019-4FD0-9AE9-D30FF7B37885 Q34994779-F0EDE104-5988-4827-B019-14918AD94C02 Q35052819-847CE89E-239D-4A72-90B9-0B48B4CA0C64 Q35079574-4426B126-BE66-450F-BB19-57E0FE833705 Q35684210-475D92CC-D043-4067-B0B3-6894B22DCF23 Q35750228-A64E8571-1892-4D62-AD3A-ACAC034A81C0 Q37603963-455D3A24-BF45-4698-868D-4F3148809BD3 Q37689883-7D124429-FF40-4E85-B1D4-EDB0F85EDD68 Q37698147-93541E2E-98F0-4AD7-8044-12032DE225B6 Q37776087-F83EC811-3973-4854-8089-590E9AD7B801 Q37834195-BD51C69E-4BE1-4749-9B0C-A0B68DFC0529 Q38019159-2179AB67-F23C-40C3-B4A4-3960FD4AAE5A Q38191477-FC2561FB-38FE-4C2D-A937-56BF531FC91F Q38243002-E53A903D-E426-40AB-BF1E-77FD3F9D8847 Q38689609-6004762C-BD3E-46BD-A07F-6B33FB3771E0 Q38994978-2C996FA6-58F0-41B2-90C2-F52D95A3DB1E Q41721818-9C34B326-B660-4AC3-9F6D-2B0121CDE9A9 Q42181050-933DE7B1-CBA8-4644-8F2F-A3BAB9C8298B

P2860

PGC-1alpha as modifier of onset age in Huntington disease.

http://www.wikidata.org/entity/Q42927080

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

PGC-1alpha as modifier of onset age in Huntington disease.

@en

PGC-1alpha as modifier of onset age in Huntington disease.

@nl

type

label

PGC-1alpha as modifier of onset age in Huntington disease.

@en

PGC-1alpha as modifier of onset age in Huntington disease.

@nl

prefLabel

PGC-1alpha as modifier of onset age in Huntington disease.

@en

PGC-1alpha as modifier of onset age in Huntington disease.

@nl

P1433

Q42927080-C41CDF6D-8A10-46CC-ACE0-F9EE8420C990

P1476

Q42927080-4C434740-7307-4DEC-9E10-5CFCAF0CB62C

P2093

Q42927080-170CD9CC-F053-466F-8F25-A7B6A7B3EE9B

Q42927080-40719AA6-5DFA-4622-9CA5-4E806303026B

Q42927080-75F54A6E-7939-47B7-A66F-EB136B4CA953

Q42927080-A32CF0E4-43CE-40FE-91A4-3A09265B2F96

P2860

Q42927080-00B6B372-9393-4CE4-BBA2-7EE3545EFBF0

Q42927080-08334A85-A43A-4120-9759-A5467410A7AC

Q42927080-0F15E85B-1F32-460E-8253-6964F32D8165

Q42927080-16E072B5-EA52-4CEB-B2D3-DA531E30B7C7

Q42927080-1E16E591-5A24-4CB8-829B-E7043FA312DE

Q42927080-33E2FD69-9684-407E-91C2-003523C3EA55

Q42927080-38C7DF3B-3888-424F-8AB9-3BA6C0700997

Q42927080-4474D299-D927-4C94-9165-D3CFAAE8F0E1

Q42927080-5335EC71-70C2-40C2-B864-0838CAD3B50D

Q42927080-5811CFD6-3BD9-421D-B8B9-2E64CD8E4F00

P2888

Q42927080-13CACC69-9EC3-435B-BC55-3529575B988D

P304

Q42927080-E78FBAFC-1352-499E-947E-10955DB435D7

P31

Q42927080-01BD762A-12BE-4438-AAFE-07FA75EB966B

P356

Q42927080-1470FADC-2677-4B5F-9453-E5FA48341F1F

P478

Q42927080-0E6BE9AD-7E56-410D-87AF-5B85A9622D6B

P50

Q42927080-0F34D81E-F484-4CB9-BA63-054EEFB7257C

P577

Q42927080-81ECF2A4-C719-48A6-9B80-43867C41CB65

P5875

Q42927080-05C06110-AB48-4438-8C2C-126EDFBE91CF

P6179

Q42927080-8CA6E7CB-36C9-4F3E-BD6A-5041CBEEC196

P698

Q42927080-6E49861B-C999-4756-A1BF-28BB776338C1

P921

Q42927080-0D50964A-BF9C-4C97-AA36-23A1D5A614CE

P932

Q42927080-FDE20043-88A9-4C31-BF0E-CE9D02359AB1

P356

P1433

Molecular Neurodegeneration

P1476

PGC-1alpha as modifier of onset age in Huntington disease.

@en

P2093

Elahe Taherzadeh-Fard

http://www.w3.org/2001/XMLSchema#string

Jürgen Andrich

http://www.w3.org/2001/XMLSchema#string

Larissa Arning

http://www.w3.org/2001/XMLSchema#string

Stefan Wieczorek

http://www.w3.org/2001/XMLSchema#string

P2860

Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator

Huntingtin-associated protein-1 is a modifier of the age-at-onset of Huntington's disease

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.

The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease

Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators

Genome-wide significance for a modifier of age at neurological onset in Huntington's disease at 6q23-24: the HD MAPS study.

A genome scan for modifiers of age at onset in Huntington disease: The HD MAPS study.

Trinucleotide repeat length instability and age of onset in Huntington's disease.

Age of onset in Huntington disease: sex specific influence of apolipoprotein E genotype and normal CAG repeat length.

Replication of twelve association studies for Huntington's disease residual age of onset in large Venezuelan kindreds.

P2888

P304

10

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1750-1326-4-10

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-02-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23987849

http://www.w3.org/2001/XMLSchema#string

P6179

1026341443

http://www.w3.org/2001/XMLSchema#string

P698

19200361

http://www.w3.org/2001/XMLSchema#string

P921

Huntington disease

P932

2644307

http://www.w3.org/2001/XMLSchema#string